Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

774 Features
From sepsis to depression

31 May 06

DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured today
LeadDiscovery

The problem of catheter infections plus advances in the treatment of colorectal cancer

30 May 06

DailyUpdates 30th May: As the drug discovery sector returns after various public holidays around the world, we too return with another edition of DailyUpdates. Amongst the 60 or so features today, we highlight work at Kane Biotech conducted in an attempt to reduce the major problem of catheter infection, plus news on the development of a liposomal candidate designed to deliver the active metabolite of Camptosar to colorectal cancer tumors. Summaries of this work are provided below - today's edit
LeadDiscovery

Ventricular Fibrillation and Atrial Fibrillation

26 May 06

Although ventricular and atrial fibrillation represent the most common cardiac arrhymias and are associated with amongst the highest rates of cardiovascular morbidity and mortality, treatment options are suboptimal. New opportunities are however approaching the market, notably Cardiome’s RSD1235, paving the way for development by others.
LeadDiscovery

Advances in autoimmune disease therapeutics

26 May 06

DailyUpdates 25th May, 2006: Today both featured items from DailyUpdates focus on autoimmune disease and remarkably neither are biologics. The first, a press release from Synta announces the advancement of an IL-12/IL-23 inhibitor in development for rheumatoid arthritis and IBD; the second is a review of potassium channels as targets for the treatment of multiple sclerosis.
LeadDiscovery

Improved detection of the influenza virus...New candidate for the treatment of Chronic Lymphocytic Leukemia enters the clinic

24 May 06

DailyUpdates 24th May, 2006: With the threat of influenza hanging over our heads on a seemingly continuous basis, improving the ability to rapidly and accurately identify patients infected with influenza and furthermore the strain of virus remains paramount. Today we feature research from CombiMatrix concerning their activities in this area. We also headline news coming out of Denmark's Genmab announcing the advance of HuMax-CD20, the company's CD20 monoclonal, into the clinic for the treatment
LeadDiscovery

e-Detailing in 2006 and beyond

23 May 06

Colin Williams, e-Marketing Director at PharmiWeb Solutions takes a look at the current e-detailing landscape and suggests what the future could hold for this much talked about tool for pharmaceutical sales and marketing departments.
Colin Williams

Battle of the Antidepressants

22 May 06

DailyUpdates 18th May, 2006: As the antidepressant sector continues to go through a period of turbulance we report on new data for one blockbuster from this class - Lexapro. Selected for special mention from over 50 journal articles today's feature demonstrates great timing appearing at the same time as our feature - Major Depressive Disorder. Today's edition of DailyUpdates can be seen here
LeadDiscovery

Benazepril offers hope to patients with advance renal disease

19 May 06

DailyUpdates 19th May, 2006: Today's edition of DailyUpdates (see it in full here) carries a couple of important articles on renal disease. One loks at the outcome of patients with renal dysfunction across various acute coronary syndromes. The featured article however demonstrates the efficacy of Novartis' Benazepril in treating advanced renal disease
LeadDiscovery

Hypertension: excitement grows around Novartis hypertension franchise update in Big Apple

17 May 06

Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
Datamonitor

VEGF: Same molecular target....new approaches to cancer

15 May 06

DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
LeadDiscovery

Leading by example: Amgen takes employee health seriously

15 May 06

When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
Katherine Griffiths

AVIAN FLU SUMMIT FOR BUSINESS

13 May 06

This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
Susie Wilson

Movement in cancer vaccine development plus breaking antidepressant research

12 May 06

DailyUpdates 12th May, 2006 (click here for entire bulletin): Today appears to be cancer vaccine day with two important announements being made. First off, Genitope Corporation announce the initiation of an ealry phase clinical trial of their MyVax idiotype immunotherapy; this was followed by an announcement by Biovest reporting that fast track status had been awarded to their phase 3 candidate, BiovaxID. This follows in the footsteps of the company's announcement that the FDA had approved sale
LeadDiscovery

Adult acute leukemia: demand for innovative drugs that prolong survival

11 May 06

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Datamonitor

The value of Marketing and PR in clinical research

10 May 06

Marketing and PR can play a variety of roles to support a company as it develops medicines in the modern healthcare setting. Therefore it is important that companies develop suitable Marketing and PR strategies to assist them in their business and understand how they can benefit from the tools used in these functions.
Dr Faiz Kermani

World Pharmaceutical (China) Summit 2006

10 May 06

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited

2nd Annual Specialty Pharmaceuticals Global Summit

25 Apr 06

Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
Ed Drilon

17th International Contracting & Negotiating Clinical Trails

25 Apr 06

The Definitive Conference for Clinical Research Contract Professionals!
Glenn Pascual

Canada's Hidden Pharma Potential

06 Apr 06

Given its proximity to the huge US market, Canada is often overlooked with respect to its contribution to the pharmaceutical sector. Yet it is a well-established market in which all the major players are active and it has a vibrant R&D environment, both for traditional pharmaceutical companies and emerging biotech companies.
Dr Faiz Kermani

Mergers emerging in Japan

06 Apr 06

Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but in recent times this attitude appears to have changed. Key mergers currently underway include Sankyo and Daiichi Pharmaceutical, Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical (who now operate as Astellas), and a tie-up between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dr Faiz Kermani

China's Challenge to Pharma

06 Apr 06

China is a country that is rapidly modernising and as its economy grows its consumer base is changing. Many international biopharmaceutical companies have started to invest in China and believe that in the long-term the healthcare market offers huge commercial potential.
Dr Faiz Kermani

What is RSS

05 Apr 06

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
Mike Wood

Search Engine Marketing Health Pharmaceutical Labs clinical

30 Mar 06

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Elias KAI

Study supports aggressive use of atorvastatin (Lipitor)

29 Mar 06

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
LeadDiscovery

Diagnosing acute congestive heart failure

28 Mar 06

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
LeadDiscovery

PABORD 2006

27 Mar 06

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
ANDREW CLARK

6th Annual e-Clinical Trials

23 Mar 06

e-Clinical Trials continue to be used more and more by the market leaders - There is no doubt though that the industry is soon to go fully electronic, so don't get behind the game... Our delegates have been demanding we run this event for the last 6 years! Here is what they have said about our past events: "...one of the best. I have learned a great deal about many of the important issues associated with e-Clinical Trials", Clinical Trial Manager/EDC Liason, Forest Labs Inc. "Informatio
Amir Sebahat

Cdk5 inhibitors as novel candidate analgesics

22 Mar 06

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
LeadDiscovery

Pharma IQ announces inaugural event in Pharma Sales Force Effectiveness

21 Mar 06

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
Rachel Davis

Big Challenges For Pharma

06 Mar 06

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Ed Bowsher

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.